Thiogenesis Therapeutics, Corp. to Present at the Virtual Investor Forum
Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biotechnology firm, is gearing up to showcase its innovative work at the upcoming Life Sciences Virtual Investor Forum. This event, set to take place on December 11, offers an excellent opportunity for current and prospective investors to gain insights into the company's latest developments.
Event Details and Participation
During the forum, Brook Riggins, the Chief Financial Officer and director of Thiogenesis, will be presenting live. Interested participants can tune in to the event, which is designed to be interactive, allowing investors to ask questions directly to the company in real-time. For those who cannot attend live, Thiogenesis will provide a recorded version of the presentation afterward, ensuring everyone has access to the information shared.
How to Register and Attend
To facilitate a smooth experience, it is highly recommended that attendees pre-register for the event. This process includes running an online system check that will help expedite participation. By registering early, investors can also receive important updates regarding the event.
Recent Highlights from Thiogenesis Therapeutics
Thiogenesis has been making strides in the field of rare mitochondrial and metabolic diseases. Recently, the company announced significant plans, including:
- Initiating a submission for an Investigational New Drug (IND) application for a Phase 3 clinical trial targeting cystinosis in the U.S.
- Presenting positive interim analysis results from an ongoing Phase 2 clinical trial for MELAS (Mitochondrial Encephalopathy Lactic Acidosis and Stroke).
- Obtaining clearance for an IND to kickstart a Phase 2a clinical trial focused on Leigh syndrome spectrum, in partnership with a renowned pediatric hospital in the U.S.
- Receiving Confirmatory Guidance from the European Medicines Agency (EMA) for filing an Investigational Medicinal Product Dossier (IMPD) for Pediatric MASH, preparing for a proposed Phase 2 trial in Europe.
About Thiogenesis Therapeutics
Based in San Diego, CA, Thiogenesis Therapeutics is dedicated to developing advanced therapies for serious pediatric diseases that currently have significant unmet needs. Their flagship candidate, TTI-0102, is undergoing active clinical trials and aims to address various metabolic disorders effectively.
About Virtual Investor Conferences
Virtual Investor Conferences (VIC) hosts interactive events that enable publicly traded companies to engage directly with investors. This platform replicates the essential elements of traditional investor conferences while incorporating modern digital enhancements to facilitate broader reach and interaction.
Contact Information
If you're interested in learning more about Thiogenesis Therapeutics or the upcoming forum, you can reach out to:
Thiogenesis Therapeutics
Brook Riggins, Director and CFO
Email: info@thiogenesis.com
Tel.: (888) 223-9165
Frequently Asked Questions
What is the purpose of the Life Sciences Virtual Investor Forum?
The purpose of the forum is to provide a platform for companies like Thiogenesis to present their developments to investors and allow for real-time interaction.
How can I participate in the event since it is virtual?
Interested individuals can register online to attend the event and can access it through their computers or devices.
What recent achievements has Thiogenesis Therapeutics accomplished?
Thiogenesis Therapeutics has announced plans for several clinical trials and reported positive interim results, showcasing their dedication to pediatric health.
Who is presenting on behalf of Thiogenesis at the forum?
Brook Riggins, the CFO and director of Thiogenesis, will be the presenter at the Life Sciences Virtual Investor Forum.
What are the contact details for Thiogenesis Therapeutics?
You can contact Brook Riggins via email at info@thiogenesis.com or call (888) 223-9165 for more information.